NCT01513733View on ClinicalTrials.gov

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2016

Conditions
Prostate Cancer
Interventions
DRUG

tasquinimod

tasquinimod 0.25 mg continuously

DRUG

tasquinimod 0.25 mg; 0.5 mg

tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated

DRUG

tasquinimod 0.25 mg; 0.5 mg; 1.0 mg

tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated

Trial Locations (2)

27710

Duke Cancer Institute, Durham

60637

The University of Chicago, Chicago

All Listed Sponsors
lead

Andrew J. Armstrong, MD

OTHER

NCT01513733 - The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer | Biotech Hunter | Biotech Hunter